BioAge Labs Inc. (BIOA) vs Eupraxia Pharmaceuticals Inc. (EPRX)
A side-by-side comparison of BioAge Labs Inc. and Eupraxia Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BIOA
BioAge Labs Inc.
$6.31HealthcareDelayed quote: Oct 6, 2026, 11:35 AM EDT
EPRX
Eupraxia Pharmaceuticals Inc.
$7.98HealthcareDelayed quote: Oct 6, 2026, 11:34 AM EDT
Total return — BIOA vs EPRX
growth of $100 · dividends reinvested · last 2yBIOA -65.3% (-41.1%/yr)EPRX +194.7% (+71.7%/yr)EPRX compounded faster over this window
Log scale — wide-divergence pair
BIOA EPRX
BIOA vs EPRX: by the numbers
- •EPRX is the larger company ($267M vs $237M market cap).
- •Both run net losses; EPRX's is the smaller (0.00% vs -912.25% net margin).
Metrics side by side
Valuation
| Metric | BIOA | EPRX |
|---|---|---|
| P/S ratio | 22.92 | N/A |
| P/B ratio | 0.63 | 2.63 |
Profitability
| Metric | BIOA | EPRX |
|---|---|---|
| Gross margin | 99.39% | 0.00% |
| Operating margin | -1026.28% | 0.00% |
| Net margin | -912.25% | 0.00% |
| ROE | -25.20% | -38.33% |
| ROIC | -28.14% | -43.56% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.